[144] ResMed Inc. SEC Filing

Rhea-AI Filing Summary

ResMed (RMD) Form 144 notice: An insider intends to sell 2,575 shares of ResMed common stock on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $739,289.14 and shows 146,414,839 shares outstanding. The securities were reported as acquired in connection with an option granted on 11/16/2023 and listed as acquired and scheduled for sale on 08/18/2025. The transaction is shown as a cash sale through the named broker. The filer states they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine insider sale of a small block of stock, likely immaterial to company valuation.

The notice reports a sale of 2,575 shares valued at $739,289.14 executed through a retail broker on the NYSE. For a company with 146,414,839 shares outstanding, this represents a de minimis percentage of outstanding equity. The shares were derived from an option granted on 11/16/2023 and shown as acquired and sold on 08/18/2025, indicating the transaction stems from prior option compensation rather than a new financing or corporate event. From a capital-structure and market-impact perspective, the sale is routine and unlikely to materially affect valuation or liquidity.

Compliance & Risk Analyst

TL;DR: Form 144 disclosure appears procedurally complete but limited in detail; no material adverse issues disclosed.

The filer certifies absence of undisclosed material adverse information and notes the sale is to be processed in cash via Fidelity Brokerage Services. The filing does not report other sales in the past three months. Documentation ties the shares to an option grant dated 11/16/2023. Based solely on the form contents, there are no red flags regarding compliance or undisclosed liabilities; the disclosure is consistent with a permitted insider sale under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2575	739289.14	146414839	08/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2025	Option Granted - 11/16/2023	Issuer			2575	08/18/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ResMed (RMD) Form 144 disclose about the sale?

The filing discloses a proposed sale of 2,575 common shares on the NYSE through Fidelity with an aggregate market value of $739,289.14.

How many ResMed shares are outstanding per the Form 144?

146,414,839 shares outstanding are reported in the notice.

What is the origin of the shares being sold in the RMD Form 144?

The shares stem from an option grant dated 11/16/2023, with the acquisition and sale dates shown as 08/18/2025.

Which broker is handling the ResMed insider sale?

Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI) is listed as the broker of record.

Does the Form 144 report other securities sold in the past three months for RMD?

No. The filing states "Nothing to Report" for securities sold during the past three months.